S. aureus CRISPR/Cas9 Antibody

Catalog Number
50 μg/ 25 μl
  Bulk order
Other format

Monoclonal antibody raised in mouse against the N-terminus of the S. aureus Cas9 nuclease (CRISPR-associated protein 9) using a recombinant protein.

Lot10µg/50µg: 001 // 100µg: 002
Concentration2 μg/μl
Species reactivityMouse
PurityProtein G purified
PrecautionsThis product is for research use only. Not for use in diagnostic or therapeutic procedures.
Applications Suggested dilution References
Western Blotting 1:4,000 Fig 1
Immunoprecipitation 5 μg/IP Fig 2
Immunofluorescence 1:400 Fig 3
  • Validation data

    CRISPR/Cas9 Antibody validated in WB

    Figure 1. Western blot analysis using the Diagenode monoclonal antibody directed against S. aureus CRISPR/ Cas9
    Western blot was performed on protein extracts from HEK293 cells (lane 1), HEK293 cells transfected with S. aureus CRISPR/Cas9 (lane 2) and HeLa cells transfected with S. pyogenes Cas9 (lane 3) using the Diagenode antibody against CRISPR/Cas9 (Cat. No. C15200230), diluited 1:4,000 in PBS-T containing 3% NFDM. The marker is shown on the left, position of the Cas9 protein is indicated on the right.

    CRISPR/Cas9 Antibody validated in IP

    Figure 2. IP using the Diagenode monoclonal antibody directed against S. aureus CRISPR/Cas9
    IP was performed on whole cell extracts (200 μg) from HEK293 cells transfected with a Cas9 expression vector (lane 1, 3 and 5), or untransfected cells (lane 2, 4 and 6) using 5 μg of the Diagenode antibody against CRISPR/Cas9 (Cat. No. C15200230). The immunoprecipitated proteins were subsequently analysed by Western blot. The results obtained with the Cas9 antibody are shown in lane 3 and 4. The negative control (IP with beads only) is shown in lane 5 and 6, the input (10 μg) is shown in lane 1 and 2.

    CRISPR/Cas9 Antibody validated in IF

    Figure 3. Immunofluorescence using the Diagenode monoclonal antibody directed against S. aureus CRISPR/Cas9
    Transiently transfected U2OS cells expressing SaCas9-T2A-GFP were fixed with 3.7% formaldehyde, permeabilized in 0.5% Triton-X-100 and blocked in PBS containing 2% BSA for 2 hours at RT. The cells were stained with the S. aureus CRISPR/Cas9 antibody (cat. No. C15200230) diluted 1:400 in blocking solution at 4°C o/n, followed by incubation with an anti-mouse secondary antibody coupled to DyLight594 for 1 h at RT (left figure). Nuclei were counter-stained with Hoechst 33342 (right). The middle figure shows IF with an anti-GFP antibody.

  • Target Description

    CRISPR systems are adaptable immune mechanisms which are present in many bacteria to protect themselves from foreign nucleic acids, such as viruses, transposable elements or plasmids. The CRISPR/Cas9 (CRISPR-associated protein 9 nuclease) system from S. pyogenes was the first to be adapted for inducing sequence-specific double stranded breaks and targeted genome editing. This system is unique and flexible due to its dependence on RNA as the moiety that targets the nuclease to a desired DNA sequence and can be used to induce indel mutations, specific sequence replacements or insertions and large deletions or genomic rearrangements at any desired location in the genome. In addition, Cas9 can also be used to mediate upregulation of specific endogenous genes or to alter histone modifications or DNA methylation, Recently, the CRISPR/Cas9 from S. aureus (UniProtKB/Swiss-Prot entry J7RUA5) was also shown to be suitable for humane genome editing. The S. aureus CRISPR/Cas9 has the advantage that it’s smaller and therefore easier to transfect cells with, whereas the efficiency and specificity are similar.

  •  Applications
    Western blot : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies. Learn more about: Load... Read more
    Immunoprecipitation Read more
    Immunofluorescence: Diagenode offers huge selection of highly sensitive antibodies validated in IF. Immunofluorescence using the Diagenode monoclonal antibody directed against CRISPR/Cas9 HeLa cells transfected with a Cas9 expression vector (... Read more
  •  Documents
    S. aureus CRISPR/Cas9 monoclonal antibody tds DATASHEET
    Datasheet of the S. aureus CRISPR/Cas9 monoclonal antibody
    Antibodies you can trust POSTER
    Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of lar...
    Epigenetic Antibodies Brochure BROCHURE
    More than in any other immuoprecipitation assays, quality antibodies are critical tools in many e...
    Accurate QC to optimize CRISPR/Cas9 genome editing specificity POSTER
    The CRISPR/Cas9 technology is delivering superior genetic models for fundamental disease res...
  •  Safety sheets
    S.aureus CRISPR/Cas9 antibody SDS GB en Download
    S.aureus CRISPR/Cas9 antibody SDS US en Download
    S.aureus CRISPR/Cas9 antibody SDS BE nl Download
    S.aureus CRISPR/Cas9 antibody SDS BE fr Download
    S.aureus CRISPR/Cas9 antibody SDS FR fr Download
    S.aureus CRISPR/Cas9 antibody SDS ES es Download
    S.aureus CRISPR/Cas9 antibody SDS DE de Download
    S.aureus CRISPR/Cas9 antibody SDS JP ja Download
  •  Publications

    How to properly cite this product in your work

    Diagenode strongly recommends using this: S. aureus CRISPR/Cas9 Antibody (Diagenode Cat# C15200230-50 Lot# 10µg/50µg: 001 // 100µg: 002). Click here to copy to clipboard.

    Using our products in your publication? Let us know!

    Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice.
    Xu L, Lau YS, Gao Y, Li H, Han R
    Previous studies from others and us have demonstrated that CRISPR genome editing could offer a promising therapeutic strategy to restore dystrophin expression and function in the skeletal muscle and heart of Duchenne muscular dystrophy (DMD) mouse models. However, the long-term efficacy and safety of CRISPR genome-e...

    Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
    Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, Robinson-Hamm JN, Bulaklak K, Castellanos Rivera RM, Collier JH, Asokan A, Gersbach CA
    Duchenne muscular dystrophy (DMD) is a monogenic disorder and a candidate for therapeutic genome editing. There have been several recent reports of genome editing in preclinical models of Duchenne muscular dystrophy, however, the long-term persistence and safety of these genome editing approaches have not been addre...

    CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency.
    Matharu N, Rattanasopha S, Tamura S, Maliskova L, Wang Y, Bernard A, Hardin A, Eckalbar WL, Vaisse C, Ahituv N
    A wide range of human diseases result from haploinsufficiency, where the function of one of the two gene copies is lost. Here, we targeted the remaining functional copy of a haploinsufficient gene using CRISPR-mediated activation (CRISPRa) in and heterozygous mouse models to rescue their obesity phenotype. Transgeni...

  •  Related products


  • EpiPlant 2024
    Clermont-Ferrand, France
    Jul 10-Jul 12, 2024
 See all events


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy